Overview

Study of Avelumab-M3814 Combinations

Status:
Recruiting

Trial end date:
2022-05-17

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Antibodies, Monoclonal
Avelumab
Peposertib